Defence Therapeutics Inc. (OTCMKTS:DTCFF) Short Interest Up 1,266.7% in January

Defence Therapeutics Inc. (OTCMKTS:DTCFF) saw a large increase in short interest in January. As of January 31st, there was short interest totalling 4,100 shares, an increase of 1,266.7% from the January 15th total of 300 shares. Based on an average daily volume of 64,900 shares, the short-interest ratio is presently 0.1 days.

Defence Therapeutics Stock Performance

DTCFF stock remained flat at $0.78 during midday trading on Wednesday. The firm’s fifty day moving average is $0.48 and its two-hundred day moving average is $0.46. Defence Therapeutics has a fifty-two week low of $0.27 and a fifty-two week high of $1.49.

Defence Therapeutics Company Profile

Defence Therapeutics Inc engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments.